drugset / Trial / NCT01185080

Efficacy Study in Allergic Rhinitis Patients After Intranasal Administration of AZD8848

NCT01185080 ↗

Phase 2 Completed 93 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary purpose of this study is to investigate effect, tolerability and safety of different dosing regimens of AZD8848 administered intranasally to seasonal allergic rhinitis patients out of season in an allergen challenge model.

Timeline

Start
2010-09
Primary completion
2010-12
Completion
2012-01

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD8848 Small molecule 20 ug Intranasal
Subject AZD8848 Small molecule 60 ug Intranasal

Indications